30.81
+3.98%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zymeworks
From its filings with the US Securities and Exchange Commission
Zymeworks is based in Middletown, Delaware and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ZYME. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $106.0m and a net loss of $81.1m. At that date it held total assets of $346.5m and shareholders' equity of $268.5m.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty cash flows and selectively invest in high-quality assets while retaining the flexibility to return capital to stockholders.
Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and internal innovation, supported by disciplined capital allocation and a strengthened financial foundation through expected milestone payments and royalties from existing commercial partners. We pursue this strategy by discovering or acquiring and developing a diversified portfolio of preclinical or clinical healthcare assets while also evaluating strategic partnership opportunities to transfer certain costs and risks related to clinical development and/or commercialization to our strategic partners and secure the right to receive potential future royalty and milestone revenues. The following elements collectively support the execution of our strategy.
Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Apr 2017
- Employees
- 264
- Website
- zymeworks.com ↗
- Head office
- 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Kenneth GalbraithChairman of the Board, Chief Executive Officer, since 2022
- Mr. Neil KlompasPresident, Chief Operating Officer, since 2022$1.9m
- Dr. Christopher AstleChief Financial Officer, Senior Vice President, since 2021
- Dr. Paul MooreChief Scientific Officer
- Dr. Neil JosephsonChief Medical Officer$3.5m
- Ms. Lota ZothLead Independent Director, since 2016$263,020
- Mr. Troy CoxIndependent Director$224,724
- Dr. Kenneth HillanIndependent Director$228,694
- Dr. Susan MahonyIndependent Director$225,988
- Dr. Kelvin NeuIndependent Director$219,574
- Mr. Hollings RentonIndependent Director$224,135
- Dr. Natalie SacksIndependent Director$232,157
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 73
- Environment
- 53
- Social
- 99
- Governance
- 68
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zymeworks employs 264 employees in Vancouver, Canada, focusing on biotechnology innovation.
- Zymeworks' Azymetric platform enables bispecific antibodies to bind multiple targets simultaneously.
- Zymeworks' lead product ZW25 targets HER2 with a bispecific antibody approach.
Weaknesses
- Zymeworks has 264 employees, which is a small team for a clinical-stage biopharmaceutical company.
- Zymeworks' ZW25 is a lead product candidate still in clinical development.
- Zymeworks' ZW49 combines ZW25 with ZymeLink ADC platform for tumor targeting.
Opportunities
- Zymeworks' ZymeLink ADC platform offers potential for new antibody-drug conjugate therapies.
- Zymeworks' EFECT platform enables fine-tuned immune cell modulation for therapeutic applications.
- Zymeworks' clinical-stage biopharmaceutical focus aligns with growing health care demand.
Threats
- Zymeworks faces competition from other biotechnology firms in the Health Care sector.
- Zymeworks' clinical-stage development may encounter regulatory hurdles in the Health Care industry.
- Zymeworks' reliance on a single lead product ZW25 could pose business risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.